List of Excipients in Branded Drug GALANTAMINE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Patriot Pharmaceuticals LLC	GALANTAMINE HYDROBROMIDE	galantamine hydrobromide	10147-0881	CELLULOSE, MICROCRYSTALLINE
Patriot Pharmaceuticals LLC	GALANTAMINE HYDROBROMIDE	galantamine hydrobromide	10147-0881	CROSPOVIDONE
Patriot Pharmaceuticals LLC	GALANTAMINE HYDROBROMIDE	galantamine hydrobromide	10147-0881	FERRIC OXIDE YELLOW

Generic Drugs Containing GALANTAMINE

Company	Ingredient	NDC	Excipient
West-Ward Pharmaceuticals Corp	galantamine	0054-0090	ANHYDROUS LACTOSE
West-Ward Pharmaceuticals Corp	galantamine	0054-0090	CELLULOSE, MICROCRYSTALLINE
West-Ward Pharmaceuticals Corp	galantamine	0054-0090	CROSPOVIDONE

What are the Most Frequently-Used Excipients in GALANTAMINE?

# Of NDCs	Excipient
1	AMMONIA
1	ANHYDROUS LACTOSE
14	CELLULOSE, MICROCRYSTALLINE

Galantamine Excipient Strategy and Commercial Opportunities

Last updated: September 6, 2026

Galantamine is a mature small-molecule Alzheimer’s drug with limited active-substance exclusivity and substantial generic competition. Commercial value has shifted from molecule ownership to formulation performance, manufacturing efficiency, patient adherence, and differentiated delivery formats. The strongest excipient opportunities are in extended-release multiparticulates, low-volume oral liquids, orally disintegrating tablets, taste masking, moisture control, and excipient systems that support robust dissolution across generic manufacturing platforms.

What is galantamine and which dosage forms are commercially relevant?

Galantamine is a reversible acetylcholinesterase inhibitor approved for the symptomatic treatment of mild-to-moderate Alzheimer’s disease. In the United States, it is marketed as galantamine hydrobromide in immediate-release tablets, extended-release capsules, and oral solution products. Brand products include Razadyne and Razadyne ER, formerly marketed as Reminyl in some markets.[1][2]

Product type	Typical strengths	Administration	Core formulation issue
Immediate-release tablet	4 mg, 8 mg, 12 mg	Twice daily	Dose titration, swallowability, dissolution
Extended-release capsule	8 mg, 16 mg, 24 mg	Once daily	Controlled release, bead coating, alcohol and food robustness
Oral solution	Commonly 4 mg/mL	Twice daily	Taste, dosing accuracy, microbial preservation
Potential ODT or orally dispersible tablet	Not universally approved	Once or twice daily	Rapid disintegration, taste masking, mechanical strength

Galantamine therapy requires dose escalation to reduce gastrointestinal adverse effects. That creates formulation demand for low-strength units, divisible dosing, reliable dose measurement, and patient-friendly administration. The commercial target is not only the final dose but also the titration sequence.

What excipients are used in galantamine formulations?

The exact excipient composition differs by manufacturer and dosage form. U.S. product labels and DailyMed records identify excipients used in marketed products, while the FDA Inactive Ingredient Database provides precedent for route-specific excipient use.[1][3]

Immediate-release tablets

Immediate-release galantamine tablets generally require:

• A filler or diluent for tablet mass and content uniformity
• A binder for granule or tablet strength
• A disintegrant for rapid breakup
• A lubricant and glidant for manufacturing performance
• A film-coating system for appearance, handling, and swallowing

Common excipient classes include lactose or other polyols, microcrystalline cellulose, crospovidone or croscarmellose sodium, povidone, colloidal silicon dioxide, magnesium stearate, and hypromellose-based coatings. The commercial objective is a fast and reproducible dissolution profile without excessive tablet hardness.

Galantamine is administered at relatively low milligram strengths. Low-dose products create content-uniformity risk because small changes in blend segregation, particle-size distribution, or API-to-excipient ratio can materially affect dose accuracy. Direct compression is attractive where the API and excipient particle properties support it. Wet granulation can improve flow and content uniformity but adds water exposure and process complexity.

Extended-release capsules

Extended-release galantamine is the most technically defensible formulation segment. The product uses a once-daily release profile and is generally manufactured as multiparticulate units filled into capsules. The formulation may use coated pellets or beads with:

• An inert starter core
• An API-containing drug layer
• A seal coat
• A functional rate-controlling polymer
• A pore former or channeling agent
• An outer protective layer

Relevant polymer classes include ethylcellulose, cellulose acetate derivatives, methacrylate copolymers, hypromellose, and polyvinyl acetate-based systems. The choice depends on target release, coating permeability, processability, and regulatory precedent.

The key performance variables are coating weight gain, polymer permeability, pellet-size distribution, curing conditions, residual solvent, and capsule-fill uniformity. These variables affect the release curve more than the nominal excipient identity alone.

Oral solution

An oral solution has the simplest manufacturing architecture but the highest sensory and use-related risk. Galantamine hydrobromide is water-soluble enough to support liquid development, but the formulation still requires control of:

• pH
• Buffer capacity
• Sweetness and bitterness
• Preservative effectiveness
• Container compatibility
• Dose-measuring accuracy
• Chemical and microbiological stability

Potential excipient categories include purified water, sweeteners, flavor systems, buffers, chelating agents, viscosity modifiers, and preservatives. Taste masking is commercially important because galantamine therapy is used in older adults who may already have swallowing difficulty, polypharmacy burden, or reduced appetite.

An oral solution can be differentiated through a calibrated oral syringe, low-volume dosing, preservative optimization, and improved palatability. A high-viscosity vehicle may improve mouthfeel but can impair dose transfer from the bottle or syringe. The product must balance sensory performance with accurate measurement.

What excipient strategy best supports galantamine generic development?

The most defensible strategy is a dosage-form-specific platform rather than a single universal excipient package.

Development objective	Preferred excipient strategy	Main risk
Low-cost immediate-release tablet	Direct-compression blend with robust disintegrant and flow aid	Content uniformity and dissolution variability
High manufacturing flexibility	Roller-compacted or wet-granulated formulation	Added process steps and stability burden
Once-daily product	Multiparticulate polymer-coated beads	Complex scale-up and coating control
Improved patient acceptance	Taste-masked ODT or oral solution	Sensory failure and excipient exposure limits
Low-volume liquid	Concentrated aqueous vehicle with optimized flavor system	Bitterness, preservative and dosing issues
Pediatric or dysphagia-oriented product	Dispersible tablet, sprinkle capsule, or calibrated liquid	Regulatory bridging and usability evidence

Content uniformity and particle engineering

Galantamine products contain low doses relative to total tablet mass. A supplier can create value through engineered API particles, co-processed excipients, or premixes that reduce segregation. Narrow particle-size distributions and controlled bulk density can improve blend uniformity and reduce tablet-to-tablet variability.

A co-processed microcrystalline cellulose and mannitol system could support direct compression, especially where lactose avoidance or improved mouthfeel is commercially relevant. The product must still demonstrate acceptable dissolution and stability against the reference product.

Disintegration and dissolution

The disintegrant system should be selected with attention to tablet hardness, hydrophobic lubrication, and storage humidity. Excess magnesium stearate or prolonged lubrication can reduce wetting and slow dissolution. Superdisintegrants can improve breakup but may increase sensitivity to compression force or moisture.

For an abbreviated new drug application, excipient selection is constrained by the need to match reference-product dissolution across relevant media. A technically novel excipient may increase regulatory burden without creating sufficient commercial value. A familiar excipient in an optimized grade often provides the stronger cost-to-benefit profile.

Taste masking

Taste masking is a major opportunity in liquid, ODT, and dispersible formats. Galantamine’s bitterness can be addressed through:

• Polymer coating of API particles
• Ion-exchange resin complexes
• Lipid or wax-based barriers
• Cyclodextrin or complexation approaches
• Sweetener and flavor systems
• Multilayer tablet architecture

Ion-exchange resins can provide strong taste suppression but may alter release, create dose-uniformity challenges, and require careful control of particle size. Polymer-coated particles can support both taste masking and modified release, but coating integrity must remain stable during storage and administration.

What formulations are protected by galantamine patents?

Galantamine’s original active-ingredient opportunity is old, and generic formulations are widely available. The principal historical patent value was associated with the drug itself, treatment use, and extended-release delivery rather than a durable new chemical entity estate.

Patent and exclusivity position

Issue	Commercial assessment
Active ingredient	Mature and genericized
U.S. FDA approval	Approved for Alzheimer’s disease treatment
Brand product	Razadyne and Razadyne ER
Generic products	Available in immediate-release and extended-release forms
Orange Book relevance	Historical listed patents and exclusivity are more important for diligence than for current market blocking
Biosimilar exposure	Not applicable because galantamine is a small molecule
Current opportunity	Formulation differentiation, manufacturing cost, and market access

The FDA Orange Book should be checked at the time of filing or acquisition for current listed patents, pediatric exclusivity, and product-status information.[4] Historical galantamine patents have generally reached their statutory expiry or lost practical blocking power. The commercial question is therefore whether a proposed product can satisfy ANDA requirements and compete on price, supply reliability, dosage-form convenience, or channel access.

Paragraph IV challenges and litigation

Galantamine’s mature generic status means that Paragraph IV analysis is primarily relevant to specific formulation or delivery claims rather than the molecule as a whole. An ANDA applicant may challenge listed patents through Paragraph IV certification when an applicable patent remains listed in the Orange Book.[5]

The most relevant litigation risks are:

1. A formulation patent covering release-controlling beads or coating architecture.
2. A method-of-use patent tied to a particular dosing regimen or patient population.
3. A patent covering a specific liquid, taste-masking, or multiparticulate system.
4. Manufacturing patents that create process constraints for a particular extended-release product.

No biosimilar litigation framework applies. Galantamine is regulated as a conventional small molecule, and generic entry proceeds through the ANDA pathway rather than the biosimilar pathway.

When does galantamine lose exclusivity and what does that mean for generic entry?

Galantamine has already passed the primary exclusivity period associated with its original approval. U.S. generic products are marketed, and generic entry risk is therefore immediate rather than an upcoming cliff.

Generic launch scenarios

Scenario	Likely market effect	Excipient implication
Additional IR tablet entrants	Price erosion and pharmacy substitution	Lowest-cost, robust direct-compression platform
Additional ER capsule entrants	Moderate technical barrier	Bead-coating and dissolution expertise
Liquid competitors	Channel-specific differentiation	Taste, preservative, and dosing-device optimization
ODT or dispersible entrant	Potential adherence niche	Taste masking and rapid disintegration
Authorized or branded generic	Reduced differentiation	Supply reliability and contracting discipline

Immediate-release galantamine is the most exposed to price competition because the technology is comparatively accessible. Extended-release products provide more protection from rapid commoditization because multiparticulate coating, dissolution matching, and scale-up are harder.

What FDA regulatory issues affect galantamine excipient selection?

The principal U.S. regulatory pathway for a conventional generic is an ANDA demonstrating pharmaceutical equivalence and bioequivalence to the reference product.[6] Excipients must be acceptable for the route and dosage form, supported by FDA precedent, and controlled through appropriate specifications.

Key regulatory issues include:

• Inactive Ingredient Database precedent
• Maximum daily exposure from the proposed dose
• Residual solvents and elemental impurities
• Microbial quality for oral liquids
• Preservative effectiveness
• Container-closure compatibility
• Dissolution similarity
• Stability under ICH conditions
• Dose uniformity across titration strengths
• Manufacturing reproducibility at commercial scale

For extended-release products, in vitro dissolution is central but may not independently establish therapeutic equivalence. The applicant must control formulation variables that can affect in vivo release. For liquids, the container, dosing syringe, and label instructions are part of the product-performance system.

Novel excipients can create differentiation but may require more extensive toxicology and regulatory justification. For a mature drug with strong price pressure, established excipients are usually commercially superior unless the new excipient solves a visible problem such as bitterness, food sensitivity, or long-term release variability.

How strong is the galantamine formulation patent estate?

The formulation patent estate is materially stronger than the active-ingredient estate only where claims are narrow, technically reproducible, and difficult to design around. Extended-release multiparticulate systems have the greatest potential for residual technical differentiation.

Patent-strength assessment

Patent category	Relative strength	Design-around risk
Broad galantamine composition claims	Low	High
Basic tablet excipient combinations	Low to moderate	High
Specific ER bead architecture	Moderate	Moderate
Defined coating polymer and weight range	Moderate	Moderate
Taste-masked particle system	Moderate	Moderate to high
Specific oral-solution composition	Moderate	High
Manufacturing process with critical parameters	Moderate	Moderate
Method-of-use claims	Variable	Depends on claim scope and listing status

A formulation patent is commercially stronger when it claims measurable structural or process parameters, such as coating thickness, polymer ratio, release windows, or particle-size limits. Broad claims to conventional excipients are more vulnerable to invalidity and design-around arguments.

Which companies and suppliers have commercial opportunities?

The opportunity set includes generic manufacturers, excipient producers, specialty coating suppliers, CDMOs, and packaging companies.

Excipient and technology opportunities

1. Co-processed direct-compression excipients for low-dose uniformity.
2. Functional coating systems for once-daily multiparticulates.
3. Taste-masking polymers and ion-exchange resins.
4. Low-peroxide and low-moisture excipient grades for stability-sensitive products.
5. Oral-liquid flavor and preservative systems.
6. Calibrated oral syringes and senior-friendly packaging.
7. CDMO services for pellet layering, fluid-bed coating, and dissolution optimization.
8. Analytical packages for comparative dissolution and extractables/leachables.

The strongest commercial position is likely to come from integrated formulation and manufacturing services rather than commodity excipient sales. A supplier that can provide the excipient, process parameters, analytical method, and scale-up support has more negotiating leverage with generic manufacturers.

How does galantamine compare with competing Alzheimer’s drugs?

Galantamine competes with donepezil and rivastigmine in the cholinesterase-inhibitor segment. Donepezil has the broadest generic penetration and the strongest ODT precedent. Rivastigmine has a commercially important transdermal patch, creating a different excipient and device opportunity. Galantamine’s main formulation advantage is the established once-daily extended-release capsule.

Drug	Main generic dosage forms	Key formulation opportunity	Main commercial constraint
Galantamine	IR tablet, ER capsule, oral solution	ER beads, liquid taste masking, ODT	Mature generic pricing
Donepezil	Tablet, ODT, oral solution in some markets	ODT and swallowability	Heavy generic competition
Rivastigmine	Capsule, oral solution, transdermal patch	Adhesive systems and delivery devices	Patch manufacturing complexity

Galantamine is less attractive as an API exclusivity play than as a formulation platform for adherence-oriented products.

What is the commercial outlook and revenue exposure?

Revenue exposure is concentrated in generic volume, not protected brand pricing. The largest addressable opportunities are likely to come from:

• High-volume immediate-release tablets with low manufacturing cost
• Extended-release products with fewer qualified competitors
• Oral solutions distributed through long-term-care and specialty pharmacy channels
• Patient-friendly dosage forms for swallowing difficulty
• Regional products using locally accepted excipients and packaging
• Contract manufacturing for small and mid-sized generic companies

A new entrant should not rely on premium pricing solely from a different excipient list. Commercial differentiation must connect the formulation to a measurable benefit: once-daily adherence, lower pill burden, improved taste, easier dose titration, lower tablet weight, or more consistent release.

What geographic coverage matters for galantamine formulations?

U.S. development should prioritize FDA Orange Book status, ANDA precedent, and U.S. inactive-ingredient exposure limits. European development requires attention to national product histories, European Pharmacopoeia standards, and excipient labeling requirements. Emerging markets may offer greater room for oral liquids, low-cost tablets, and local packaging but can have different registration and bioequivalence expectations.

A global excipient strategy should maintain:

• Pharmacopoeial compliance across target markets
• Dual-source supply for critical polymers and coating materials
• Regional flavor and sweetener adaptation
• Common core formulation where dissolution and stability permit
• Separate packaging solutions for humidity-sensitive products

Key Takeaways

• Galantamine is a mature, genericized small molecule with limited remaining core exclusivity value.
• Immediate-release tablets are mainly a cost and manufacturing-efficiency opportunity.
• Extended-release multiparticulates offer the strongest technical and commercial differentiation.
• Oral solutions require concentrated work on taste, preservation, dosing accuracy, and packaging.
• ODT and dispersible products may support adherence-focused positioning but face taste-masking and regulatory challenges.
• Established excipients are generally preferable to novel excipients for ANDA economics.
• The most valuable suppliers will combine excipient technology with coating, analytical, and scale-up services.
• Orange Book and patent checks remain necessary for any specific product launch, particularly for extended-release formulations.
• Biosimilar risk does not apply because galantamine is a conventional small molecule.
• Generic entry is already established, so commercial success depends on cost, supply, patient usability, and dosage-form performance.

FAQs

Is galantamine still patent protected?

The original galantamine product and core therapeutic technology are mature, and generic products are marketed. Any remaining patent risk is more likely to involve a specific formulation, manufacturing process, or listed method of use than the active ingredient itself.

Which galantamine dosage form has the highest formulation barrier?

The extended-release capsule generally has the highest barrier because it requires multiparticulate coating, controlled dissolution, process uniformity, and scale-up reproducibility.

Can a novel excipient create market exclusivity for galantamine?

A novel excipient alone does not create product exclusivity. It may support patent protection if incorporated into a novel and non-obvious formulation, but regulatory, safety, and design-around issues can reduce its commercial value.

Is an oral solution of galantamine commercially attractive?

Yes, particularly for patients with swallowing difficulty and long-term-care channels. The main challenges are bitterness, preservative effectiveness, dosing accuracy, packaging, and stability after opening.

Does galantamine have biosimilar competition?

No. Galantamine is a small-molecule drug. Competition proceeds through generic pharmaceutical equivalents, typically under the ANDA pathway in the United States.

References

1. U.S. Food and Drug Administration. (2023). Razadyne prescribing information. https://www.accessdata.fda.gov
2. National Library of Medicine. (2024). DailyMed: Galantamine hydrobromide. https://dailymed.nlm.nih.gov
3. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
5. U.S. Food and Drug Administration. (2024). ANDA submissions: Content and format. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda
6. U.S. Food and Drug Administration. (2024). Generic drug facts. https://www.fda.gov/drugs/generic-drugs/generic-drug-facts